Journal Logo

Poster Session II: Myeloproliferative neoplasms – Clinical

PS1462 SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY

Maffioli, M.1; Giorgino, T.2; Mora, B.1; Iurlo, A.3; Elli, E.4; Finazzi, M.C.5; Caramella, M.6; Rumi, E.7; Carraro, M.C.8; Polverelli, N.9; D’Adda, M.10; Malato, S.11; Rossi, M.12; Molteni, A.13; Vismara, A.14; Sissa, C.15; Spina, F.16; Anghilieri, M.17; Barraco, D.1; Porta, M.G. Della12; Passamonti, F.18

Author Information
doi: 10.1097/01.HS9.0000564112.29135.44
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.